Nektar corrects REZPEG Phase 1b data; atopic dermatitis EASI-75 rate now 41% vs 29% reported by Lilly

NEKTAR THERAPEUTICS

Highest REZPEG dose (24 µg/kg) in atopic dermatitis achieved 83% mean EASI improvement (p=0.002 vs placebo).
EASI-75 response rate corrected from previously reported 29% to 41% (NRI) and 58% as observed.
Psoriasis data also corrected: PASI-50 rate rose to 32% (NRI) and PASI-75 to 21% (NRI); p-values remained non-significant.
Errors discovered after Lilly returned rights; independent statistical firm reanalyzed raw data.
Nektar plans to start Phase 2b study in moderate-to-severe atopic dermatitis in October 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.